Best Infectious Diseases Companies in Denmark
The 33 best Infectious Diseases companies in Denmark in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Minervax.
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Infectious Diseases companies in Denmark
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Minervax Developer of vaccines against life-threatening infections in newborns | $197M | 36 mo ago | Series C | 7 | Per Fischer CEO | WordPressMySQLPHP+18 | — | — |
| 2 | Bavarian Nordic Developer of therapeutic vaccines against cancer and infectious diseases | $185M | 21 mo ago | Public | 35 | — | FlowplayerBootstrapMicrosoft Advertising+8 | 1,103 patents MVA viral vectors for cancer immunotherapy and vaccine production | — |
| 3 | Santaris Pharma Developer of RNA-targeted therapies for infectious and metabolic diseases | $104M | 172 mo ago | Acquired | 60 | Peter Sondermann Founder & CEO | — | 512 patents Therapeutic antisense oligonucleotides targeting TNF receptors and microRNAs | — |
| 4 | SNIPR Biome Developer of CRISPR-based microbial gene therapy to target pathogenic bacteria precisely | $54M | 14 mo ago | Series B | 48 48 → 46 (-4%) | Morten Sommer Co-Founder | — | 142 patents Patents concentrated in health & consumer products | — |
| 5 | Synklino Developer of drugs for the treatment of chronic viral infections | $32M | 52 mo ago | Series A | 5 | Thomas Kledal CEO & Co-Founder | — | 6 patents Ex vivo organ preservation and infection‑prevention perfusion compositions for transplantation | — |
| 6 | UNION Therapeutics Developer of small molecule antibiotic drugs for treating bacterial infections | $25M | 52 mo ago | Series B | 36 | Rasmus Toft-Kehler Co-Founder | — | 165 patents Patents concentrated in health & consumer products | — |
| 7 | BluSense Diagnostics Developer of a next-generation diagnostics platform to diagnose infectious diseases | $14M | 81 mo ago | Deadpooled | 35 | — | — | 5 patents Centrifugal microfluidic lab‑on‑a‑chip platforms for sample processing and detection | — |
| 8 | Evaxion Biotech Developer of immunotherapies for the treatment of cancer and infectious diseases | $5M | 34 mo ago | Public | 61 61 → 51 (-16%) | Andreas Holm Mattsson Co-Founder | — | 148 patents Designing engineered proteins and predictive tools for cancer immunotherapy and bacterial vaccines | — |
| 9 | Pcovery Developer of fungal therapy by targeting an essential and highly conserved component of the fungal cell… | $4M | 153 mo ago | Deadpooled | 3 | — | — | — | — |
| 10 | Adenium Biotech Developer of antimicrobial peptides for multi-drug resistant bacterial infections | $4M | 172 mo ago | Deadpooled | 5 | — | WordPressMySQLPHP+8 | 134 patents Antimicrobial peptide therapeutics and recombinant production for TB and inflammatory diseases | — |
| 11 | ExpreS2ion Biotechnologies Provider of recombinant protein production using an insect expression platform | $2M | 79 mo ago | Public | 32 | — | WordPressMySQLPHP+20 | 35 patents Glyco‑engineered recombinant proteins with xylosylated N‑glycans for vaccines | — |
| 12 | Watgen Medical Developer of medical device for treating atopic dermatitis | $2M | 85 mo ago | Seed | 1 | Peter Bjerring Founder | — | — | — |
| 13 | AdaptVac Developer of therapeutic and prophylactic vaccines | $888K | 79 mo ago | Funding Raised | 6 | — | — | — | — |
| 14 | GlyProVac Developer of glycoprotein-based vaccine against bacterial infections | $354K | 73 mo ago | Seed | 3 | Ann Andersen Co-Founder | — | — | — |
Top 12 Infectious Diseases companies in Denmark
#1
Series B · Copenhagen, Capital Region of Denmark · founded 2011 · 48 employees$53.9Mraised▾
Developer of CRISPR-based microbial gene therapy to target pathogenic bacteria precisely. The company focuses on treating difficult conditions like multidrug-resistant infections, cystic fibrosis, IBD, and certain cancers by engineering the human microbiome.
- Aug 2025Series B$40.6M
- Dec 2024Venture Debt$21.1M
- Jan 2024Series B$11.9M
- Jun 2022Series A$8.4M
#2
Public · Hellerup, Capital Region of Denmark · founded 1994 · 35 employees$185Mraised▾
Developer of therapeutic vaccines against cancer and infectious diseases. The company has proprietary poxviral-based vaccine platform technologies, to develop medicines that address a wide variety of infectious diseases and cancers. The company has developed a pipeline for Smallpox, RSV, COVID-19 and Immuno-oncology.
- Jan 2025Grant (prize money)$1.5M
- Mar 2021Post IPO$183.4M
#3
Series C · Hellerup, Capital Region of Denmark · founded 2010 · 7 employees$196.9Mraised▾
Developer of vaccines against life-threatening infections in newborns. Its lead vaccine candidate GBS-NN is a single fusion protein as an antigen against the N-terminal regions. The candidate claims to have been shown to elicit a protective immune response in animal models.
- Oct 2023Series C$57.2M
- Dec 2022Conventional Debt$53.2M
- Dec 2022Series B$23.4M
- Apr 2022Series B$44.8M
#4
Series B · Hellerup, Capital Region of Denmark · founded 2013 · 36 employees$25.1Mraised▾
Developer of small molecule antibiotic drugs for treating bacterial infections. It focussed on developing therapies that overcome antibiotic resistance for the treatment of bacterial infections and related disorders. Its lead candidate, ATx201, is a small molecule topical treatment for bacterial skin infections. It also has programsATx202 and ATx401 which are topical and oral treatments for acne and C. difficile infections.
- Jun 2022Series B$6.9M
- Feb 2021Series B$25.1M
- Jun 2020Series A$2.2M
- Oct 2019Series A$1.2M
#5
Series A · Copenhagen, Capital Region of Denmark · founded 2017 · 5 employees$32.3Mraised▾
Developer of drugs for the treatment of chronic viral infections. The lead candidate of the company is SYN002 an immunotoxin that targets US28 for the treatment of Cytomegalovirus (CMV).
- Jun 2022Series A$31.9M
- Nov 2021Seed$33.8K
- Sep 2020Seed—
- Jan 2020Seed$164.5K
#6
Public · Copenhagen, Capital Region of Denmark · founded 2008 · 61 employees$5.3Mraised▾
Developer of immunotherapies for the treatment of cancer and infectious diseases. The company's drug candidates include EVX-B1 against Staphylococcus aureus, EVX-02 for melanoma, EVX-03 for multiple cancer, and EVX-B2 against P. aeruginosa. The company has developed immuno-oncology platforms called Pioneer and Eden which uses algorithms to identify and select neoepitopes, tumor-specific mutations, and protein antigens to generate an anti-cancer immune response.
- Dec 2023Post IPO$5.3M
#7
Acquired · Copenhagen, Capital Region of Denmark · founded 2003 · 60 employees$104.3Mraised▾
Developer of RNA-targeted therapies for infectious and metabolic diseases. The company uses the proprietary Locked Nucleic Acid (LNA) platform and drug discovery platform to develop therapeutics with a focus on infectious diseases and cardiometabolic disorders. Its lead candidate is miravirsen (SPC3649), a short modified RNA molecule for the treatment of hepatitis C infections.
- 2012Series C$12M
- Jan 2011Series C$14M
- May 2008Grant (prize money)$9M
- Dec 2007Series B$30M
#8
Deadpooled · Copenhagen, Capital Region of Denmark · founded 2014 · 35 employees$14.1Mraised▾
Developer of a next-generation diagnostics platform to diagnose infectious diseases. The product includes BluBox which is a portable IVD device for single-drop-of-blood diagnostics for dengue and the COVID-19 and another device ViroTrack for virus identification. It is based on centrifugal microfluidics technology, magnetic nanoparticle physics, and Blu-Ray optics.
#9
Public · Copenhagen, Capital Region of Denmark · founded 2010 · 32 employees$2.1Mraised▾
Provider of recombinant protein production using an insect expression platform. The platform technology uses a non-viral Drosophila cell expression platform for protein production. The ExpreS2 kit allows customers to set up the ExpreS2 platform in-house. ExpreS2ion Biotech also partners with companies for the development of vaccines for breast cancer, coronavirus, and tropical diseases, such as malaria and chikungunya.
- Apr 2020Grant (prize money)$942.9K
- Dec 2019Grant (prize money)$285.6K
- Oct 2019Conventional Debt$814.7K
- Jan 2017Grant (prize money)$52.6K
#10
Deadpooled · Copenhagen, Capital Region of Denmark · founded 2009 · 3 employees$4.1Mraised▾
Developer of fungal therapy by targeting an essential and highly conserved component of the fungal cell membrane. The approach is to use structure-based drug discovery on membrane protein drug targets. The target (membrane protein) is highly conserved across a wide range of fungal species and is not found in mammalian cells.
- Jan 2014Series A$4.1M
- Jun 2013Grant (prize money)$6.3M
#11
Deadpooled · Copenhagen, Capital Region of Denmark · founded 2011 · 5 employees$4Mraised▾
Developer of antimicrobial peptides for multi-drug resistant bacterial infections. The lead compound AA139, one of the non-hemolytic and non-cytotoxic amino acids antimicrobial peptide of the Arenicin family is isolated from the lugworm for pneumonia and Urinary tract infection (UTI). Other products include AP138 for MRSA Implant infections and pneumonia.
- Jun 2012Seed$1.9M
- Aug 2011Seed$2.1M
#12
Seed · Vejle, South Denmark · founded 2018 · 1 employees$1.8Mraised▾
Watgen Medical manufactures medical devices for treating atopic dermatitis. It sterilizes and hydrogenizes tap water for treating skin diseases. Tempered water is the perfect environment for bacteria growth in standard hot water, leading to different skin diseases. The device provides water that is hydrolyzed and the bacterial growth in hydrolyzed water is very slow.
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.